In addition, the mammalian target of rapamycin (mTOR) inhibitor ridaforolimus (RIDA) significantly delayed disease progression in patients with advanced soft tissue sarcoma but did not significantly improve overall survival (28). The gene discussed is MTOR; the disease is soft tissue sarcoma.